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William J. Murphy, Ph.D. (chair),1 Andrew S. Artz, M.D., M.S.,2 Richard E. Champlin, M.D.,3
John Koreth, M.B.B.S., D.Phil.,4 Dan L. Longo, M.D.5A serious dichotomy currently exists in hematopoietic stem cell transplantation (HSCT) and cancer
research. Cancer is a disease that predominantly affects older people, yet there is a paucity of cancer research
addressing the very unique needs of this population. Even basic biologic processes that exist in aging (decline
in immune competency, increased sensitivities to therapies, etc.) are only beginning to be understood.
Proportionally, the vast majority of cancer preclinical research does not involve the use of aged animals
due to expense and time. This seriously hampers realistic extrapolation of preclinical findings to the general
population affected by cancer. This report recommends research priorities that can help close the gaps in our
understanding of aging as it relates to HSCTand cancer.
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Demographics indicate that our society is aging.
Cancer predominantly affects people over the age 55.
For hematologic malignancies, the use of hematopoi-
etic stem cell transplantation (HSCT) is a powerful
means to eradicate the cancer.
The use of HSCT has been increasingly indicated
for older patients, but many potentially eligible
patients are not being given the option. The use of
HSCT also has been shown to have applications in
other medical problems including solid tumors, ge-
netic disorders, autoimmunity, organ transplantation,
and even HIV. HSCT or stem cell rescue may also
play an important role in radioprotection and bioter-
rorism. HSCT, particularly allogeneic HSCT, has nu-
merous barriers that must be overcome to improve its
efficacy. Studies in preclinical models and clinical trials
have conclusively shown that managing older patients
represents a unique set of challenges for the physician.
Toxicities of cytoreductive therapies are heightened
in older patients. Poor immune function in older peo-
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recently, allogeneic HSCT was not recommended in
people over the age of 55 years. Even with reduced
intensity conditioning, the complications of allogeneic
HSCT (graft-versus-host disease, opportunistic infec-
tion, transplant-related morbidities) remain high.
Despite the increasing numbers of older patients,
we know very little about the factors in older people
that influence the outcome of HSCT. The science of
aging needs to be applied to HSCT. Basic questions
regarding the effects of age on hematopoiesis, immune
function and recovery, response to insult and stress are
critically needed. This needs to be coupled with clini-
cal studies regarding the effects of age on outcomes
and quality of life as well as overcoming barriers to
generating these data. From the basic science perspec-
tive, a strong emphasis should be placed on encourag-
ing aging studies which are often time-consuming and
expensive.Many of the preclinical models often used in
understanding the effects of HSCT and means to
increase its efficacy use young mice, analogous to per-
forming a transplant on an adolescent. From the clin-
ical perspective, there needs to be an assessment of the
barriers to obtaining unbiased data regarding the
effects of age on outcomes, particularly when using
HSCT. An understanding of the barriers that the phy-
sician faces in treating older patients where HSCT is
considered to be an option needs to be systemically
studied.ISSUES AND PRIORITIES
The Scientific Affairs Council of ASBMT has
formed a committee to attempt to identify the more
Biol Blood Marrow Transplant 15:1638-1639, 2009 1639ASBMT Committee Reportpressing issues in the use of HSCT in older patients.
Comprised by a cross-section of researchers and clini-
cians, the panel identified several areas that deserve
special attention and are of critical importance if
HSCT is to be applied to older patients in any of
a variety of indications. These areas are tied to the
Research Priorities established by ASBMT in 2008.
Areas of emphasis:
1. Biology of Aging (including impact of age on
stem cell biology, inflammatory responses to cytore-
ductive conditioning, immune assessment and status,
development of more appropriate preclinical models).
The biological effect of aging on all organ systems is an
understudied area. Baseline data are needed in order to
apply and understand the impact of HSCT. Effects of
aging on hematopoiesis and the hematopoietic micro-
environment as well as the impact of age on the donor
HSCs are needed. Effects of age on the immune system
as well as the thymic involution associated with age
need to be further explored. Finally, the effects of
age on solid organ responses to cytoreductive condi-
tioning are greatly needed, not only for HSCT, but
also for cancer therapies in general in order to under-
stand the increased toxicities encountered in the older
patient. Development and use of appropriate animal
models are also needed along with an understanding
of their limitations.
2. Study of HSCT outcomes in older patients
(including study of barriers to performing clinical
trials with older patients). In addition to molecular
approaches, research should focus on clinically rele-
vant functional assessments of physiologic reserve
and the influence of comorbidities on outcomes.
Various versions of so-called ‘‘geriatric assessment’’
have been developed to measure particular features
associated with homeostatic control of key organ func-
tions. Efforts are needed to develop predictors of
recovery after preparative regimens used in HSCT.
Age-related declines in liver and renal function
together with genetic influences on drug metabolism
and distribution may alter the pharmacology of the
various interventions that support patients undergoing
HSCT. Research efforts need to include assessments
of functional outcomes over time similar to those per-
formed in longitudinal studies in normal aging. These
could include retrospective analyses as well as sub-
group analysis of prospective trials. The parameters
would cover survivorship, quality of life, emergence
of late complications and determination if preventative
interventions exist that can minimize risk.
3. Indications for use of HSCT in aging (regen-
erative medicine, bioterrorism, cancer). As HSCT is
increasingly applied to older patients with hematologic
malignancies, based on recent successes with advanced
melanoma, it is also important to expand utilization of
HSCT in older patients with other cancers. Further,
the use of HSCs or IPSCs in regenerative medicineneeds to be better explored and applied in the popula-
tion that perhaps needs it most: older people. Finally,
the use of HSCT in radioprotection and recovery in
the event of bioterrorism needs to be much further de-
veloped, given the high likelihood that older patients
would be significantly affected from such an attack.
4. Immune reconstitution after HSCT in the
older patient and susceptibility to opportunistic in-
fections.The delayed immunological recovery associ-
ated with the older HSCT patient results in increased
susceptibility to opportunistic infections and increased
risk of relapse. Studies are needed to understand this
delay in immune recovery and develop means to accel-
erate it. Means to promote not only T cell but B cell
recovery and the generation of functional and protec-
tive cell-mediated and humoral immune responses to
relevant pathogens (CMV, fungal, bacterial) are
urgently needed.
5. Chronic graft-vs-host disease. Chronic
GVHD also is an ASBMT research priority, but is
even more prevalent in the older HSCT recipient.
The mechanisms underlying chronic GVHD patho-
physiology are still not known. Also needed are better
preclinical models, means for intervention or preven-
tion and understanding of the effects of age on disease
progression and onset.
The two most significant barriers associated with
aging studies revolve around 1) the cost, time and
lack of appropriate animal models used for preclinical
and basic science studies which limits extrapolation to
man, and 2) the clinical barriers associated with per-
forming accurate and in-depth clinical assessment
using the older patient which consists of both fear of
increased toxicity and increased complications associ-
ated with this population.RECOMMENDATIONS
HSCT is used for the treatment of multiple disease
states ranging from cancer to aplastic anemia to im-
mune deficiency disorders. As such, the impact of age
on treatment outcomes crosses the missions of multi-
ple NIH institutes including NIA, NCI, NHLBI,
and NIAID.
It is recommended that a consensus conference be
initiated by these institutes to address the unique issues
pertaining to aging research. It is hoped that this con-
ference would lead to cooperation among the institutes
to marshal resources to encourage and facilitate aging
research as it pertains to HSCT. This could be by
establishing an RFAs on aging and HSCT research
encompassing both preclinical and clinical studies, by
addressing issues on limitations of resources and the
unique needs of aging research, and by engaging other
federal agencies and private industry on the need for
further emphasis on aging research.
